France Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

France Point-of-Care Glucose Testing Market

The France point-of-care glucose testing market is witnessing significant traction in the market. This is attributed to rise in prevalence of type-1 as well as type-2 diabetes in the country. In addition, surge in diabetes cases has boosted the demand for glucose testing products, thereby driving the market growth. However, there are certain restraints of the market growth, including stringent regulatory framework governing the medical devices in France. Compliance with rigorous quality standards and clinical validation poses significant challenges for market players, particularly for new entrants, therefore hampering the market development. In addition, the dynamic reimbursement policies affect the affordability and accessibility of point-of-care glucose testing products, thus restraining the market. 

On the contrary, the France point-of-care glucose testing market presents significant growth opportunities for market players. The integration of digital technology and data analytics into glucose testing devices is anticipated to open new avenues for growth. This integration offers real-time monitoring, data sharing, and remote healthcare management, thereby promising improved patient outcomes and healthcare efficiency. In addition, exploring the untapped areas of the market offers key players the opportunity to expand their geographical reach. Moreover, the aging population, coupled with changing lifestyles and dietary habits, is projected to expand the customer base of key players. The France point-of-care glucose testing market is projected to witness various trend in the future. One of the most prominent trends emerging in the market is increase in emphasis on noninvasive glucose monitoring technologies. Requisition for painless and user-friendly devices for glucose testing is expected to drive the demand for product innovation in the future. Furthermore, advanced sensors and wearables exhibit the potential to revolutionize the market. 

The France point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is bifurcated into lancing devices & strips and blood-glucose meters. As per application, the market is divided into type-1 diabetes and type-2 diabetes. According to end user segment, the market is classified into hospitals & clinics, home care settings, and others. 

The various key players operating in the France point-of-care glucose testing market are Abbott, Roche Diagnostics, Arysta Lifescience, Lifescan, Sanofi, AgaMatrix, Nipro Diagnostics, Demeditec Diagnostics, Glucose Diagnostics and Acon Laboratories. Qualitative insights of the market depict the diverse perspectives and strategies of these key players. New product development is a key element of the market where the players strive to introduce novel solutions that offer precise glucose monitoring as well as enhance the overall user experience. In addition, R&D efforts are crucial to innovate the existing technologies and create next-generation glucose testing solutions. Furthermore, understanding end-user perceptions is essential to cater to the variable needs of consumers. Tailoring products and services to meet these distinct preferences requires a deep understanding of consumer behavior and healthcare dynamics. Moreover, pricing strategies are prominent for market players to strike the right balance between affordability and quality to remain competitive in the market. The price points of glucose testing products are influenced by factors such as manufacturing costs, competition, and reimbursement policies. 

The Porter’s five forces analysis assists to understand the competitive scenario of the market and role of each stakeholder. The analysis includes threat of new entrants, threat of substitutes, bargaining power of buyers, bargaining power of suppliers, and competitive rivalry. The competitive rivalry among existing competitors is intense, with established players vying for market share and new entrants seeking to disrupt the conventionality of the market. The threat of new entrants is low as stringent regulations act as large barriers to entry. The bargaining power of suppliers is high, as the availability of quality raw materials and components directly impacts product quality. The bargaining power of buyers is high due to increase in awareness and boost in the number of alternatives available in the market. The threat of substitutes is significant as emerging technologies and alternative methods for glucose monitoring constantly challenge the relevance of traditional point-of-care testing solutions. 

A SWOT analysis of the France point-of-care glucose testing market reveals a multitude of strengths, weaknesses, opportunities, and threats. Strengths of the market include its established network of healthcare providers, robust research ecosystem, and surge in awareness of diabetes management. However, weaknesses include complex regulatory landscape, pricing pressures, and ever-evolving reimbursement policies. On the contrary, opportunities for the market include integration of digital health solutions, catering to the aging population, and expansion into untapped markets. Contrarily, threats include technological disruptions, fluctuating market dynamics, and challenges of ensuring product quality & compliance in a highly regulated environment. 

Key players operating in the France point-of-care glucose testing market include Abbott, Roche Diagnostics, Arysta Lifescience, Lifescan, Sanofi, AgaMatrix, Nipro Diagnostics, Demeditec Diagnostics, Glucose Diagnostics and Acon Laboratories. 

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in France point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of France point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the France point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ Acon Laboratorie

Scope of France Point-of-Care Glucose Testing Market Report

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

2.1. CXO Perspective

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market Size and Forecast, By Product Type

4.2. Lancing Devices and Strips

4.3. Blood-Glucose Meter

5.1. Overview

5.1.1. Market Size and Forecast, By Application

5.2. Type-1 Diabetes

5.3. Type-2 Diabetes

6.1. Overview

6.1.1. Market Size and Forecast, By End User

6.2. Hospitals and Clinics

6.3. Home Care Settings

6.4. Others

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Abbott

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. Roche Diagnostics

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. Arysta Lifescience

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. Lifescan

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. Sanofi

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.5.7. Key strategic moves and developments

8.6. AgaMatrix

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.6.7. Key strategic moves and developments

8.7. Nipro Diagnostics

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.7.7. Key strategic moves and developments

8.8. Demeditec Diagnostics

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.8.7. Key strategic moves and developments

8.9. Glucose Diagnostics

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.9.7. Key strategic moves and developments

8.10. Acon Laboratories

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performance

8.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 03. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 04. ABBOTT: KEY EXECUTIVES

TABLE 05. ABBOTT: COMPANY SNAPSHOT

TABLE 06. ABBOTT: OPERATING SEGMENTS

TABLE 07. ABBOTT: PRODUCT PORTFOLIO

TABLE 08. ABBOTT: KEY STRATERGIES

TABLE 09. ROCHE DIAGNOSTICS: KEY EXECUTIVES

TABLE 10. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 11. ROCHE DIAGNOSTICS: OPERATING SEGMENTS

TABLE 12. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 13. ROCHE DIAGNOSTICS: KEY STRATERGIES

TABLE 14. ARYSTA LIFESCIENCE: KEY EXECUTIVES

TABLE 15. ARYSTA LIFESCIENCE: COMPANY SNAPSHOT

TABLE 16. ARYSTA LIFESCIENCE: OPERATING SEGMENTS

TABLE 17. ARYSTA LIFESCIENCE: PRODUCT PORTFOLIO

TABLE 18. ARYSTA LIFESCIENCE: KEY STRATERGIES

TABLE 19. LIFESCAN: KEY EXECUTIVES

TABLE 20. LIFESCAN: COMPANY SNAPSHOT

TABLE 21. LIFESCAN: OPERATING SEGMENTS

TABLE 22. LIFESCAN: PRODUCT PORTFOLIO

TABLE 23. LIFESCAN: KEY STRATERGIES

TABLE 24. SANOFI: KEY EXECUTIVES

TABLE 25. SANOFI: COMPANY SNAPSHOT

TABLE 26. SANOFI: OPERATING SEGMENTS

TABLE 27. SANOFI: PRODUCT PORTFOLIO

TABLE 28. SANOFI: KEY STRATERGIES

TABLE 29. AGAMATRIX: KEY EXECUTIVES

TABLE 30. AGAMATRIX: COMPANY SNAPSHOT

TABLE 31. AGAMATRIX: OPERATING SEGMENTS

TABLE 32. AGAMATRIX: PRODUCT PORTFOLIO

TABLE 33. AGAMATRIX: KEY STRATERGIES

TABLE 34. NIPRO DIAGNOSTICS: KEY EXECUTIVES

TABLE 35. NIPRO DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 36. NIPRO DIAGNOSTICS: OPERATING SEGMENTS

TABLE 37. NIPRO DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 38. NIPRO DIAGNOSTICS: KEY STRATERGIES

TABLE 39. DEMEDITEC DIAGNOSTICS: KEY EXECUTIVES

TABLE 40. DEMEDITEC DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 41. DEMEDITEC DIAGNOSTICS: OPERATING SEGMENTS

TABLE 42. DEMEDITEC DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 43. DEMEDITEC DIAGNOSTICS: KEY STRATERGIES

TABLE 44. GLUCOSE DIAGNOSTICS: KEY EXECUTIVES

TABLE 45. GLUCOSE DIAGNOSTICS: COMPANY SNAPSHOT

TABLE 46. GLUCOSE DIAGNOSTICS: OPERATING SEGMENTS

TABLE 47. GLUCOSE DIAGNOSTICS: PRODUCT PORTFOLIO

TABLE 48. GLUCOSE DIAGNOSTICS: KEY STRATERGIES

TABLE 49. ACON LABORATORIES: KEY EXECUTIVES

TABLE 50. ACON LABORATORIES: COMPANY SNAPSHOT

TABLE 51. ACON LABORATORIES: OPERATING SEGMENTS

TABLE 52. ACON LABORATORIES: PRODUCT PORTFOLIO

TABLE 53. ACON LABORATORIES: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 10. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)

FIGURE 11. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)

FIGURE 12. FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: FRANCE POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2022

FIGURE 20. ABBOTT: NET SALES, 2020-2022* ($MILLION)

FIGURE 21. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 22. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 23. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 24. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 25. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 26. ARYSTA LIFESCIENCE: NET SALES, 2020-2022* ($MILLION)

FIGURE 27. ARYSTA LIFESCIENCE: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 28. ARYSTA LIFESCIENCE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 29. LIFESCAN: NET SALES, 2020-2022* ($MILLION)

FIGURE 30. LIFESCAN: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 31. LIFESCAN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 32. SANOFI: NET SALES, 2020-2022* ($MILLION)

FIGURE 33. SANOFI: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 34. SANOFI: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 35. AGAMATRIX: NET SALES, 2020-2022* ($MILLION)

FIGURE 36. AGAMATRIX: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 37. AGAMATRIX: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 38. NIPRO DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 39. NIPRO DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 40. NIPRO DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 41. DEMEDITEC DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 42. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 43. DEMEDITEC DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 44. GLUCOSE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)

FIGURE 45. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 46. GLUCOSE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 47. ACON LABORATORIES: NET SALES, 2020-2022* ($MILLION)

FIGURE 48. ACON LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 49. ACON LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%